Alnylam Pharma (ALNY) AI Stock Analysis

• Market Cap: $56.81B
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): 1727.2
• Beta (1Y): 0.96
• Revenue Growth: 53.24%
• EPS Growth: N/A
• Country: US
• Employees: 2,230
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.84
• Shares Outstanding: 132,113,820
• 10 Day Avg. Volume: 987,199
• 30 Day Avg. Volume: 1,073,652
• PEG Ratio: 2.84
• Price to Book (P/B): 447.73
• Price to Sales (P/S): 13.36
• P/FCF Ratio: -705.29
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 19.53
• Enterprise Value/Gross Profit: 23.25
• Enterprise Value/Ebitda: 336.00
• 1Y Price Target: $498.37
• Price Target Upside: 23.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $477.00 ▲(17.94% Upside)

Alnylam Pharma's overall score is driven by strong earnings call results and robust revenue growth, tempered by high leverage and valuation concerns. The technical indicators suggest moderate market sentiment, while the high P/E ratio indicates potential overvaluation.

Positive Factors

Revenue Growth

The significant revenue growth demonstrates Alnylam's strong market position and successful product launches, indicating a robust demand for its innovative therapies.

Pipeline Advancements

The advancement of late-stage trials highlights Alnylam's commitment to expanding its therapeutic offerings, potentially leading to new revenue streams and market leadership.

Product Launch Success

The successful launch and adoption of AMVUTTRA underscore Alnylam's effective commercialization strategy, enhancing its competitive advantage in the RNAi therapeutic market.

Negative Factors

High Leverage

Significant leverage could pose financial risks, limiting Alnylam's ability to invest in growth opportunities and affecting long-term financial stability.

Decreased Gross Margin

A decrease in gross margin may impact profitability, necessitating cost management improvements to sustain financial performance.

Increased Expenses

Rising expenses could pressure margins and require strategic cost control to maintain profitability while supporting R&D and market expansion.

Alnylam Pharma Business Overview & Revenue Model

Company Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Alnylam Pharmaceuticals generates revenue primarily through the commercialization of its proprietary drug products, particularly ONPATTRO and AMVUTTRA, which are sold to healthcare providers and patients. The company also earns revenue through collaboration agreements and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales of products developed under these partnerships. These collaborations can enhance Alnylam's financial stability and provide additional funding for research and development of new therapies. Furthermore, the company may receive grants or funding from government and non-profit organizations to support its ongoing research projects.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma shows strong revenue growth and improving profitability metrics, but faces challenges with high leverage and cash flow management. The company is on a positive trajectory with improving margins, yet needs to address its debt levels and enhance cash flow generation to ensure long-term financial stability.

Income Statement

Alnylam Pharma has shown significant revenue growth with a 30.39% increase in TTM, indicating strong sales momentum. The gross profit margin is healthy at 83.72% in 2022, but the net profit margin remains low at 1.36% in TTM, reflecting challenges in achieving profitability. The EBIT and EBITDA margins have improved but are still negative, suggesting ongoing operational inefficiencies.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 5.59 in TTM, indicating significant leverage and potential financial risk. However, the return on equity has improved to 26.13% in TTM, suggesting better utilization of equity. The equity ratio is low, highlighting a reliance on debt financing.

Cash Flow

Cash flow analysis reveals a negative free cash flow growth rate of -524.98% in TTM, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.17, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is relatively strong at 0.83, indicating some ability to convert income into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.21B	2.25B	1.83B	1.04B	844.29M	492.85M
Gross Profit	2.70B	1.92B	1.52B	868.60M	704.14M	414.80M
EBITDA	186.55M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
Net Income	43.56M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet
Total Assets	4.85B	4.24B	3.83B	3.55B	3.64B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.72B	2.69B	2.44B	2.19B	2.44B	1.87B
Total Debt	2.77B	2.74B	1.31B	1.32B	997.59M	521.19M
Total Liabilities	4.62B	4.17B	4.05B	3.70B	3.06B	2.39B
Stockholders Equity	233.89M	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow
Free Cash Flow	221.36M	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
Operating Cash Flow	265.86M	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
Investing Cash Flow	420.58M	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
Financing Cash Flow	-319.51M	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 404.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Negative. The current price of 404.46 is below the 20-day moving average (MA) of 447.40, below the 50-day MA of 454.82, and above the 200-day MA of 360.25, indicating a neutral trend. The MACD of -6.44 indicates Positive momentum. The RSI at 32.66 is Neutral, neither overbought nor oversold. The STOCH value of 5.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALNY.

Alnylam Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	81 Outperform	$18.98B	15.96	30.39%	―	18.09%	3563.21%
ARGX	79 Outperform	$55.37B	41.81	24.75%	―	89.58%	―
VRTX	78 Outperform	$112.15B	30.80	22.31%	―	10.53%	―
GMAB	76 Outperform	$19.52B	13.45	28.20%	―	24.98%	127.06%
ALNY	60 Neutral	$56.81B	1,727.16	32.73%	―	53.24%	―
BNTX	53 Neutral	$23.39B	―	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alnylam Pharma Corporate Events

Alnylam Pharma Secures $500M Credit Agreement

On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of America and other lenders, securing a $500 million revolving line of credit. This agreement, which includes a $150 million letter of credit sublimit, allows Alnylam to use the funds for working capital and general corporate purposes. The credit facility is subject to various financial covenants, including maintaining specific leverage and interest coverage ratios, and is secured by the company’s assets. The maturity date for the credit facility is September 30, 2030, with provisions for early maturity under certain conditions.

Alnylam Pharma Executes Note Repurchase Transactions

Alnylam Pharma has engaged in financial maneuvers involving convertible senior notes. The company offered and sold notes to initial purchasers under exemptions from registration, with potential issuance of up to 1,381,483 shares of common stock upon conversion. Concurrently, Alnylam executed note repurchase transactions, buying back approximately $637.8 million of its 1.00% convertible senior notes due 2027 for around $1,105.8 million, influenced by market conditions.

Alnylam Pharma Announces $500M Convertible Notes Offering

On September 8, 2025, Alnylam Pharmaceuticals announced a proposed private offering of $500 million in convertible senior notes due 2028, targeting qualified institutional buyers. The offering aims to support capped call transactions and repurchase existing notes, potentially impacting Alnylam’s stock market activity and conversion price. The company plans to use the proceeds for these financial strategies and general corporate purposes, with implications for its market positioning and stakeholder interests.